JP2019531346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531346A5 JP2019531346A5 JP2019536463A JP2019536463A JP2019531346A5 JP 2019531346 A5 JP2019531346 A5 JP 2019531346A5 JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019531346 A5 JP2019531346 A5 JP 2019531346A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- group
- substituted
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 substituted Chemical class 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 22
- 125000004429 atom Chemical group 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000001072 heteroaryl group Chemical class 0.000 claims 6
- 238000012423 maintenance Methods 0.000 claims 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 2
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 0 CC(C)c1c(*)ccc(Cc(c(C)c2)c(*)cc2OCP(OCC2)(O[C@@]2c2cccc(Cl)c2)=O)c1 Chemical compound CC(C)c1c(*)ccc(Cc(c(C)c2)c(*)cc2OCP(OCC2)(O[C@@]2c2cccc(Cl)c2)=O)c1 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022148311A JP7656574B2 (ja) | 2016-09-16 | 2022-09-16 | 甲状腺関連副作用を低下させる方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662396015P | 2016-09-16 | 2016-09-16 | |
| US201662396025P | 2016-09-16 | 2016-09-16 | |
| US62/396,015 | 2016-09-16 | ||
| US62/396,025 | 2016-09-16 | ||
| PCT/US2017/051410 WO2018053036A1 (en) | 2016-09-16 | 2017-09-13 | Method of reducing thyroid-associated side effects |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022148311A Division JP7656574B2 (ja) | 2016-09-16 | 2022-09-16 | 甲状腺関連副作用を低下させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531346A JP2019531346A (ja) | 2019-10-31 |
| JP2019531346A5 true JP2019531346A5 (enExample) | 2020-10-22 |
Family
ID=61619247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536463A Pending JP2019531346A (ja) | 2016-09-16 | 2017-09-13 | 甲状腺関連副作用を低下させる方法 |
| JP2022148311A Active JP7656574B2 (ja) | 2016-09-16 | 2022-09-16 | 甲状腺関連副作用を低下させる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022148311A Active JP7656574B2 (ja) | 2016-09-16 | 2022-09-16 | 甲状腺関連副作用を低下させる方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190255080A1 (enExample) |
| EP (1) | EP3512523A4 (enExample) |
| JP (2) | JP2019531346A (enExample) |
| KR (2) | KR20240074912A (enExample) |
| CN (2) | CN109922812A (enExample) |
| AU (1) | AU2017327383B2 (enExample) |
| CA (1) | CA3037146A1 (enExample) |
| MX (2) | MX2019003032A (enExample) |
| WO (1) | WO2018053036A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| WO2018094265A2 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| AU2020267953A1 (en) * | 2019-05-08 | 2021-11-18 | Novartis Ag | Anti-CD40 antibodies for use in treatment of T1DM and insulitis |
| RU2728261C2 (ru) * | 2019-05-22 | 2020-07-28 | Ирина Алексеевна Курникова | Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом |
| CA3147789A1 (en) * | 2019-08-19 | 2021-02-25 | Hepagene Therapeutics (HK) Limited | Heterocyclic thr-.beta. receptor agonist compound and preparation method and use therefor |
| CN112457346B (zh) * | 2019-08-19 | 2022-09-06 | 和博医药有限公司 | 一种并环THRβ受体激动剂化合物及其制备方法和用途 |
| EP4019524A4 (en) * | 2019-08-19 | 2024-01-03 | Hepagene Therapeutics (HK) Limited | HETEROCYCLIC THR-BETA RECEPTOR AGONIST COMPOUND, PREPARATION METHOD AND USE THEREOF |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| WO2026092581A1 (en) * | 2024-10-30 | 2026-05-07 | Ascletis Pharma (China) Co., Limited | Thyroid hormone receptor beta modulator alone or in combination with a modulator of glp-1r, gipr or gcgr, for use in the treatment of obesity or overweight or for treating alopecia areata |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| MXPA04012497A (es) * | 2002-07-04 | 2005-07-14 | Zealand Pharma As | Glp-1 y metodos para tratar la diabetes. |
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| US20090232879A1 (en) * | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| WO2009089093A1 (en) * | 2008-01-04 | 2009-07-16 | Quatrx Pharmaceuticals Company | Thyroid hormone receptor agonists |
| CN106344495A (zh) * | 2008-12-22 | 2017-01-25 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物 |
| WO2011038207A1 (en) * | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EP3445769A4 (en) * | 2016-04-22 | 2020-02-12 | Metabasis Therapeutics, Inc. | THYROID HORMONE RECEPTOR AGONIST AND ITS USE |
| WO2018094265A2 (en) * | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
-
2017
- 2017-09-13 WO PCT/US2017/051410 patent/WO2018053036A1/en not_active Ceased
- 2017-09-13 CN CN201780068418.8A patent/CN109922812A/zh active Pending
- 2017-09-13 CA CA3037146A patent/CA3037146A1/en active Pending
- 2017-09-13 CN CN202511838413.1A patent/CN121695155A/zh active Pending
- 2017-09-13 KR KR1020247016178A patent/KR20240074912A/ko active Pending
- 2017-09-13 KR KR1020197010782A patent/KR20190060786A/ko not_active Ceased
- 2017-09-13 MX MX2019003032A patent/MX2019003032A/es unknown
- 2017-09-13 JP JP2019536463A patent/JP2019531346A/ja active Pending
- 2017-09-13 AU AU2017327383A patent/AU2017327383B2/en active Active
- 2017-09-13 EP EP17851476.6A patent/EP3512523A4/en active Pending
- 2017-09-13 US US16/333,513 patent/US20190255080A1/en active Pending
-
2019
- 2019-03-15 MX MX2023000887A patent/MX2023000887A/es unknown
-
2022
- 2022-09-16 JP JP2022148311A patent/JP7656574B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020123241A (ru) | Полициклические соединения в качестве аллостерических ингибиторов shp2 | |
| JP2016509047A5 (enExample) | ||
| JP2020505376A5 (enExample) | ||
| JP2020506178A5 (enExample) | ||
| JP2020515610A5 (enExample) | ||
| JP2020536881A5 (enExample) | ||
| JP2021534124A5 (enExample) | ||
| JP2016505586A5 (enExample) | ||
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| JP2015532295A5 (enExample) | ||
| JP2019512505A5 (enExample) | ||
| JP2020500866A5 (enExample) | ||
| JP2022544714A5 (enExample) | ||
| JP2017505314A5 (enExample) | ||
| JP2009526761A5 (enExample) | ||
| JP2017526726A5 (enExample) | ||
| JP2014514290A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP2017518959A5 (enExample) | ||
| JP2013542996A5 (enExample) | ||
| JP2016509583A5 (enExample) | ||
| JP2012532137A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2011519360A5 (enExample) | ||
| JP2019521097A5 (enExample) |